ALKERMES | ALKS - Ebit

Prezzo Delle Azioni
27.92
Cambio Giornaliero
0.16 0.58%
Mensile
-15.14%
Annuale
-17.95%
Q1 Previsione
26.93




Ebit Cambiamento Data
AbbVie USD 5.81B 4.36B 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 157M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Coherus Biosciences USD -45.43M 3.19M 2025-03
Eli Lilly USD 8.99B 1.57B 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Heron Therapeutics USD -4.46M 5.76M 2024-09
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.11B 2.3B 2025-12
Malin Corporation EUR -1.1M 300K 2024-12
Merck USD 6.24B 1.32B 2025-12
Minerva Neurosciences USD -4.37M 1.71M 2024-09
Nektar Therapeutics USD -34.34M 3.68M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Otsuka Holdings JPY 67.25B 101.57B 2025-12
Ovoca Bio EUR -5.65M 3.45M 2022-06
Pfizer USD 4.65B 71M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12